July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
The Efficacy of Topical Bevacizumab and Sunitinib on Corneal Neovascularization in patients with Stevens-Johnson.
Author Affiliations & Notes
  • Tais Hitomi Wakamatsu
    Ophthalmology, Federal University of São Paulo, São Paulo, SP, Brazil
  • Alessandra Yoshie Takiishi
    Ophthalmology, Federal University of São Paulo, São Paulo, SP, Brazil
  • Flávio Hirai
    Ophthalmology, Federal University of São Paulo, São Paulo, SP, Brazil
  • Acácio Souza Lima
    Pharmacology, Federal University of São Paulo, São Paulo, Brazil
  • Jose Alvaro Pereira Gomes
    Ophthalmology, Federal University of São Paulo, São Paulo, SP, Brazil
  • Footnotes
    Commercial Relationships   Tais Wakamatsu, None; Alessandra Takiishi, None; Flávio Hirai, None; Acácio Lima, None; Jose Gomes, None
  • Footnotes
    Support  FAPESP 2012/09816-0
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 3329. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Tais Hitomi Wakamatsu, Alessandra Yoshie Takiishi, Flávio Hirai, Acácio Souza Lima, Jose Alvaro Pereira Gomes; The Efficacy of Topical Bevacizumab and Sunitinib on Corneal Neovascularization in patients with Stevens-Johnson.
      . Invest. Ophthalmol. Vis. Sci. 2018;59(9):3329.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : We performed a prospective, randomized, double blind, placebo controlled study to evaluate the effect of topical bevacizumab and sunitinib in the treatment of corneal neovascularization in patients with Stevens-Johnson syndrome (SJS).

Methods : 36 eyes of 26 patients (9 males and 17 females) with SJS and corneal neovascularization (≥ 2mm from the limbus) were examined in this study. Patients were randomized to 1 of 3 groups: Group 1 received carboxymethyl cellulose 0.5%, Group 2 bevacizumab 10mg/ml, and Group 3 sunitinib 5mg/ml. All treatments were administered 4 times daily for one month. All subjects underwent best correct visual acuity (BCVA), Schirmer test, tear film break up time, fluorescein/ lisamine green stainings, pachymeter, confocal scanning microscopy and photographs were taken on a slit lamp before the treatment and on months 1, 2, 3, 4, 5 and 6. The area of neovascularization was measured in pixels2.

Results : BCVA showed significant improvement in patients treated with bevacizumab on the second month after treatment (p=0.013) and with sunitinib on the fourth and sixth month after treatment (p=0.030 and p=0.029 respectively). There were no significant differences in the quantitative data of fluorescein and lisamine green stainings for those who were treated with bevacizumab and sunitinib eye drops. From the baseline visit to the last follow-up visit, mean reductions were 31.11% for bevacizumab and 33.20% for sunitinib. On month 3,4 and 6 the mean percentages of areas of corneal neovascularization in the sunitinib treated eyes were smaller compared with carboxymethyl cellulose treated group (p=0.02, p=0.01, p=0.02).

Conclusions : Topical administration of both bevacizumab and sunitinib inhibits corneal neovascularization in SJS patients. Furthermore, blocking both VEGF and platelet-derived growth factor pathways applying topical administration of sunitinib yields better results than bevacizumab.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×